The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis
Abstract
Thyroid cancer is the most common malignant tumor of the endocrine system and accounts for approximately 1% of all newly diagnosed cancer cases. The most frequent type of thyroid malignancy is papillary carcinoma, which constitutes approximately 80% of all cases. Papillary carcinomas frequently have genetic alterations leading to the activation of the MAPK signal pathway. Those include RET/PTC rearrangement and point mutations of the BRAF and RAS genes. Mutations in these genes are found in over 70% of papillary carcinomas and they rarely overlap in the same tumor. Frequent genetic alterations in follicular carcinomas, the second most common type of thyroid malignancy, include RAS mutations and PAX8-PPAR gamma rearrangement. RET point mutations are crucial for the development of medullary thyroid carcinomas. Many of these mutations, particularly those leading to the activation of the MAPK pathway, are being actively explored as therapeutic targets for thyroid cancer. Detection of these genetic alterations using molecular techniques is important for preoperative fine-needle aspiration diagnosis, prognosis and treatment of thyroid cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
World Health Organization Classification of Tumours
Fletcher, C., van den Berg, A., & Molenaar, I. (2002) · Cited by 7,079
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
Cooper, D. S., Doherty, G. M., Haugen, B. R., Kloos, R. T., Lee, S. L., Mandel, S. J., Mazzaferri, E. L., McIver, B., Sherman, S. I., & Tuttle, R. M. (2006) · Thyroid · doi:10.1089/thy.2006.16.109 · Cited by 2,016
Kimura, E. T., Nikiforova, M. N., Zhu, Z., Knauf, J. A., Nikiforov, Y. E., & Fagin, J. A. (2003) · PubMed · Cited by 1,707
Self-citationBRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Pathology and genetics of tumours of endocrine organs
DeLellis, R. A. (2004) · Cited by 1,122
Nikiforova, M. N., Kimura, E. T., Gandhi, M., Biddinger, P. W., Knauf, J. A., Basolo, F., Zhu, Z., Giannini, R., Salvatore, G., Fusco, A., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030838 · Cited by 1,042
Self-citation
Cited by
Elisei, R., Ugolini, C., Viola, D., Lupi, C., Biagini, A., Giannini, R., Romei, C., Miccoli, P., Pinchera, A., & Basolo, F. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0607 · Cited by 528
Papillary Thyroid Carcinoma Variants
Lloyd, R. V., Buehler, D., & Khanafshar, E. (2011) · Head and Neck Pathology · doi:10.1007/s12105-010-0236-9 · Cited by 277
Fiore, E., Rago, T., Provenzale, M. A., Scutari, M., Ugolini, C., Basolo, F., Di Coscio, G., Berti, P., Grasso, L., Elisei, R., et al. (2009) · Endocrine-Related Cancer · doi:10.1677/erc-09-0036 · Cited by 254
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
Capdevila, J., & Stjepanovic, N. (2014) · Biologics: Targets and Therapy · doi:10.2147/btt.s39381 · Cited by 85
PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer
Kari, S., Vasko, V. V., Priya, S., & Kirschner, L. S. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00769 · Cited by 34
Chen, H., Luo, D., Zhang, L., Lin, X., Luo, Q., Yi, H., Wang, J., Yan, X., Li, B., Chen, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17398 · Cited by 29
Genetic mutations, molecular markers and future directions in research
Patel, K. N. (2013) · Oral Oncology · doi:10.1016/j.oraloncology.2013.03.437 · Cited by 6
Metadata
- Authors
- Nikiforova, M. N., & Nikiforov, Y. E.
- Venue
- Expert Review of Molecular Diagnostics
- Publisher
- Informa UK Limited
- Published
- 2008-01
- Volume
- 8
- Issue
- 1
- Pages
- 83-95
- ISSN
- 1473-7159 (ISSN-L)
- 1744-8352
- OpenAlex
- W2109544257
- Cited by
- 277
- References
- 114
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.